The Challenge
Alex (a pseudonym), 45, was diagnosed with multiple myeloma in 2022 — a blood cancer that is hard to cure and prone to relapse. After several lines of standard therapy abroad, with two periods of remission, his disease relapsed again in November 2025. His local doctors had run out of options; CAR-T was not available in his region, leaving only a bispecific antibody whose benefit falls short of cellular therapy. Searching globally, his family learned that China had moved quickly in CAR-T and had several products approved.
The Bridge
From December 6 to 26, the international team at Beijing United Family Hospital and Alex's family exchanged about 60 emails — three a day — answering every question about eligibility, side effects, timelines, and daily life. A remote multidisciplinary consultation walked the family through the plan; when his visa stalled, the team arranged a medical certificate to clear it. On arrival in Beijing he was met with an English greeting and helped with a SIM card, apps, and an apartment with a kitchen so he could cook familiar food.
The Procedure
Workup — blood tests, bone-marrow biopsy, imaging — confirmed he was a candidate. A positive cytomegalovirus (CMV) test forced a pause; targeted treatment cleared it within two weeks. The team then used a fully-human, BCMA-targeted CAR-T therapy (equecabtagene autoleucel, Fucaso®, Nanjing IASO Biotherapeutics). BCMA is highly expressed on myeloma cells and almost absent on normal tissue, making it an ideal target. His lymphocytes were collected on January 20 and sent for manufacturing; after lymphodepleting chemotherapy, the engineered cells were reinfused in late February, with 24-hour monitoring for the key risks of CAR-T — cytokine-release syndrome (CRS) and neurotoxicity (ICANS).
The Outcome
Alex came through the observation period smoothly. His tumor burden was brought under control and his indicators returned toward normal, and he was discharged with a structured remote follow-up plan. Notably, CAR-T in China runs at roughly one-third to one-fifth of the equivalent US cost. "It was Beijing United Family's rigor and warmth that gave me a second life," he said. "The care here earned my trust."
